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BACKGROUND
WHAT IS LONG QT?
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WHAT’S THE HARM?
LQTS is either inherited or acquired
Inherited occurs in 1/2,500 live births
Caused by channel gene defects
Cannot be determined only by ECG
Diagnostic criteria useful, but not always accurate
Causes 3000-4000 deaths annually in children and young 
adults in the US alone
1993 LQTS diagnostic criteria (Schwartz, 2006).
ACQUIRED LQTS
Caused by medications
Can lead to Torsade de Pointes, ventricular tachycardia, ventricular fibrillation, and arrhythmia
Antiarrhythmics, antidepressants, antipsycotics, and antiemetics
Associated with 90 noncardiovascular drugs
Most common cause of relabeling/withdrawal of market drugs in last decade
 1990-2001: 21 withdrawn
Unclear why diverse compounds block HERG channels
2005: FDA released a Guidance for Industry
 Drugs produced before this date have not been tested
Currently unpredictable
Occurs in 1-8% of patients receiving antiarrhythmic drugs (Yang, 2002)
Risk factors include:
Female gender
Hypokalemia
Hypomagnesaemia
Bradycardia
High drug concentrations
Heart failure
But what about genetic/inherited predisposition?
FINDINGS
SILENT MUTATIONS
9 genotyped probands without clinically affected family members entered the study
46 family members examined; none affected by LQTS on ECG
Molecule diagnosis revealed 15 family members were gene carriers
This was missed by ECG and the clinical scale
Possible to be a gene carrier without a prolonged interval
13 mutations have been identified
These individuals are predisposed to the possible occurrence of drug-induced 
Torsade de Pointes
SCN5A GENE
Provides instructions for making sodium channels
One patient exposed to cisapride
Had normal QT interval prior
Developed prolonged QT interval, severe bradycardia, and repetitive torsade de pointes
Return to normal 6 days after discontinuation
Due to a genetic mutation in a sodium channel
Possesses a polymorphism more prevalent in aLQTS 
23 family members examined of the proband
11 members carry the allele
Knowing these could allow the identification of at-risk individuals
Hereditary tree (Splawski, 2002)
THE GENETIC LINK
Acquired LQTS shares many features with congenital
Genetic factors may determine susceptibility
Three main genes: KCNQ1, KCNH2, and SCN5A
Overall, ten associated
Quinidine study
LQTS occurs in individuals who are genetically predisposed, but requires an additional stressor
Genetic re-sequencing
In 31 subjects, 20 carried missense variants across a set of 79 genes
Further, 23% carry previously identified cLQTS genes
Findings suggest overlap between cLQTS and aLQTS may be greater than previously reported
FUTURE PROSPECTS
WHERE DO WE GO?
With the proper knowledge, many of these cases are preventable
Genetic screening
Genotyping costs need to fall
Genotype- based pharmacotherapy
More significantly robust genomic markers necessary
A perfectly healthy individual can be a gene carrier for a lethal syndrome
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